Benchmarking practices and research

(Health Data Warehouse transparency portal)

Join a research program

In partnership with hospitals, LogipremF has established a benchmarking program for care practices. The use of Logipren prescription software is coupled with the establishment of a centralized prescription database (Logipren Database). These data are pseudonymised (for the patient and the prescriber) within the facilities, before being sent to the Health Data Warehouse (HDW).

The primary objective is to provide neonatology and pediatrics services with comparative results of their prescription practices (benchmarking program).

The secondary objective is to provide research units with a real-world prescription database for medical studies (see ongoing research and publications below).

A Scientific and Ethical Committee has been established, comprised notably of physicians and pharmacists from all user care services, representatives of learned societies (SFN, SFPC), and research units (CEPOI, INSERM), for the management of the constituted database.

This Scientific Committee meets at least once a year and guides research using the Logipren Database.

Comparison of prescription practices

The LOGIPREN database allows for regular comparison of prescription practices between care units.

Each year, a report is drafted containing the results of each unit, as well as graphs comparing these results.

The comparison is anonymous: each care unit is associated with a number used for the presented results.

Everyone knows their own number, but not those of others. The results are analyzed annually in meetings by physicians and pharmacists from all hospitals.

Ongoing studies

  • Vaccination of premature infants: Marie-Laure Charkaluk (St-Vincent de Paul, Lille) 
  • Mupirocin: Isabelle Ligi (APHM, University Hospital La Conception)
  • Acid suppressive medications: Manon Tauzin (CHI Créteil)
  • Opiate equianalgesia: Manon Tauzin (CHI Créteil)
  • Dexmedetomidine in ventilated extremely premature babies: Camille Irving (CHI Créteil)
  • Prescriptions for children >1 year in pediatric intensive care: Béatrice Gouyon (Logipren)
  • Epoetin Beta: Roselyne Brat (CHR Orléans)

Feel free to contact us to participate or propose study topics.

Scientific articles

Diuretic drug utilization in neonates: a French prescription database analysis

Frontiers in Pharmacology, 2024

Lacobelli,S., Lorrain, S., Rabe, E., Gouyon, B., Gouyon, J.B., & Bonsante, F. (2024).

Diuretic drug utilization in neonates: a French prescription database analysis, 15:1358761.

https://doi.org/10.3389/fphar.2024.1358761

Postnatal corticosteroid exposure in very preterm infants : A french cohort study  

Frontiers in Pharmacology, 2023

Iacobelli, S., Allamèle-Moutama, K., Lorrain, S., Gouyon, B., Gouyon, J. B., Bonsante, F., & Logipren Collaborative Working Group (2023).

Postnatal corticosteroid exposure in very preterm infants: A French cohort study. Frontiers in pharmacology14, 1170842.

https://pubmed.ncbi.nlm.nih.gov/37089932/

https://doi.org/10.3389/fphar.2023.1170842

Paraben exposure through drugs in the neonatal intensive care unit : a regional chohort study

Frontiers in Pharmacology, 2023

Iacobelli, S., Commins, M., Lorrain, S., Gouyon, B., Ramful, D., Richard, M., Grondin, A., Gouyon, J. B., & Bonsante, F. (2023).

Paraben exposure through drugs in the neonatal intensive care unit: a regional cohort study. Frontiers in pharmacology, 14, 1200521.

https://pubmed.ncbi.nlm.nih.gov/37361223/

https://doi.org/10.3389/fphar.2023.1200521

Frequencies, Modalities, Doses and Duration of Computerized Prescriptions for Sedative, Analgesic, Anesthetic and Paralytic Drugs in Neonates Requiring Intensive Care: A Prospective Pharmacoepidemiologic Cohort Study in 30 French NICUs From 2014 to 2020

Frontiers in Pharmacology, 2022

Tauzin, M., Gouyon, B., Hirt, D., Carbajal, R., Gouyon, J. B., Brunet, A. C., Ortala, M., Goro, S., Jung, C., & Durrmeyer, X. (2022).

Frequencies, Modalities, Doses and Duration of Computerized Prescriptions for Sedative, Analgesic, Anesthetic and Paralytic Drugs in Neonates Requiring Intensive Care : A Prospective Pharmacoepidemiologic Cohort Study in 30 French NICUs From 2014 to 2020. Frontiers in pharmacology13, 939869. 

Copy the URL to download : https://www.logipren.com/wp-content/uploads/2022/07/2022.07.18_Article-antalgiques-M-Tauzin.pdf

https://doi.org/10.3389/fphar.2022.939869

Prescription of Aminoglycosides in 23 French Neonatal Intensive Care Units

Antibiotics, 2021

Martin-Mons, S., Gouyon, B., Lorrain, S., Abasse, S., Alexandre, C., Binson, G., Brat, R., Caeymaex, L., Couringa, Y., Desbruyeres, C., Meglio, M. D., Escourrou, G., Flamein, F., Flechelles, O., Girard, O., Kermorvant-Duchemin, E., Lapillonne, A., Lafon, C., Di Maio, M., Mazeiras, G., … Gouyon, J. B. (2021).

Prescription of Aminoglycosides in 23 French Neonatal Intensive Care Units. Antibiotics (Basel, Switzerland)10(11), 1422. 

Copy the URL to download :  https://www.logipren.com/wp-content/uploads/2022/07/2021.11.21_Prescription-of-Aminoglycosides-in-23-French-Neonatal-Intensive-Care-units.pdf

https://doi.org/10.3390/antibiotics10111422

Antibiotics prescription over three years in a French benchmarking network of 23 Level 3 Neonatal Wards

Frontiers in Pharmacology, 2020

Martin-Mons, S., Lorrain, S., Iacobelli, S., Gouyon, B., Gouyon, J. B., & B-PEN Study Group (2021).

Antibiotics Prescription Over Three Years in a French Benchmarking Network of 23 Level 3 Neonatal Wards. Frontiers in pharmacology11, 585018. 

https://www.frontiersin.org/articles/10.3389/fphar.2020.585018/abstract

https://doi.org/10.3389/fphar.2020.585018

Drug exposure for PDA closure in France: a prospective, cohort-based, analysis

European journal of clinical pharmacology.2020

Iacobelli, S., Lorrain, S., Gouyon, B., Gambacorta, S., Laforgia, N., Gouyon, J. B., & Bonsante, F. (2020).

Drug exposure for PDA closure in France: a prospective, cohort-based, analysis. European journal of clinical pharmacology76(12), 1765–1772. 

https://pubmed.ncbi.nlm.nih.gov/32740771/

https://doi.org/10.1007/s00228-020-02974-1

Characteristics of prescription in 29 Level 3 Neonatal Wards over a 2-year period (2017-2018). An inventory for future research

Public Library of Science one (Plos One),2019

Gouyon, B., Martin-Mons, S., Iacobelli, S., Razafimahefa, H., Kermorvant-Duchemin, E., Brat, R., Caeymaex, L., Couringa, Y., Alexandre, C., Lafon, C., Ramful, D., Bonsante, F., Binson, G., Flamein, F., Moussy-Durandy, A., Di Maio, M., Mazeiras, G., Girard, O., Desbruyeres, C., Mourdie, J., … Gouyon, J. B. (2019).

Characteristics of prescription in 29 Level 3 Neonatal Wards over a 2-year period (2017-2018). An inventory for future research. PloS one14(9), e0222667. 

https://pubmed.ncbi.nlm.nih.gov/31536560/

https://doi.org/10.1371/journal.pone.0222667

A Computer Prescribing Order Entry-Clinical Decision Support system designed for neonatal care: results of the 'preselected prescription' concept at the bedside

Journal of clinical pharmacy and therapeutics,2017

Gouyon, B., Iacobelli, S., Saliba, E., Quantin, C., Pignolet, A., Jacqz-Aigrain, E., & Gouyon, J. B. (2017).

A Computer Prescribing Order Entry-Clinical Decision Support system designed for neonatal care: results of the 'preselected prescription' concept at the bedside. Journal of clinical pharmacy and therapeutics42(1), 64–68. 

https://pubmed.ncbi.nlm.nih.gov/27882560/

https://doi.org/10.1111/jcpt.12474

Data protection

Data security is at the heart of our concerns.

Our teams have implemented advanced measures to ensure the confidentiality and integrity of the information we process.

All data processing related to the database is in strict compliance with current regulations:

  • The entire processing is compliant with the European General Data Protection Regulation (GDPR)
  • The evaluation of care practices is authorised by the National Commission on Informatics and Liberty (historically: DE-2017-410 then MR004, Deliberation No. 2018-155 of 3rd May 2018).
  • As regulations have evolved, an authorisation request for the establishment of a Health Data Warehouse has been submitted to the CNIL, to ensure compliance with the reuse of data collected for benchmarking purposes.

At any time, upon request, a patient’s data can be removed from the Logipren database.

To learn more (about your rights and our processing of health data), please consult our privacy policy: